ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag pharma biobusiness tuberculosis disease medicine

Take Two of These
Bob Grant | Jun 22, 2011 | 6 min read
Drugmakers are teaming up to test the disease-fighting power of combination therapies earlier in the development cycle than ever before.
Antidepressant Approvals Could Herald New Era in Psychiatric Drugs
Bianca Nogrady | Oct 1, 2019 | 9 min read
The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.
Outwitting the Perfect Pathogen
Megan Scudellari | Jan 1, 2014 | 8 min read
Tuberculosis is exquisitely adapted to the human body. Researchers need a new game plan for beating it.
Updated July 9
Track COVID-19 Vaccines Advancing Through Clinical Trials
The Scientist | Apr 7, 2020 | 10+ min read
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
Fighting the 10/90 Gap
Ricki Lewis | May 12, 2002 | 5 min read
While wealthy nations pursue drugs to treat baldness and obesity, depression in dogs, and erectile dysfunction, elsewhere millions are sick or dying from preventable or treatable infectious and parasitic diseases.1 It's called the 10/90 gap. "Less than 10% of the worldwide expenditure on health research and development is devoted to the major health problems of 90% of the population," explains Els Torreele, co-chair of a working group that provided background recently for an initiative announced

Run a Search

ADVERTISEMENT